Meet the experts

Brittany Craiglow, MD

Brittany Craiglow is Associate Professor Adjunct at Yale School of Medicine, and a double board-certified dermatologist. She practices at Yale Dermatology Associates and Yale New Haven Hospital, Connecticut, USA.

Craiglow has particular expertise in treating inflammatory skin diseases, alopecia, and disorders of keratinization.

Disclosures: Honoraria and/or fees from Aclaris Therapeutics Inc, Arena Pharmaceuticals, Pfizer, and Sanofi–Genzyme. Speaker bureaus for Eli Lilly and Company, Pfizer, Regeneron, and Sanofi–Genzyme.

Damien Hamber

Damian Hamber has a long career in IT services in a variety of roles, in particular, developing teams internationally to deliver global services to enterprise customers. Hamber volunteered for Alopecia UK for 4 years before joining the Board in 2021, supporting at events, conferences, support groups, and providing peer support.

“Many years on I was sitting in a coffee shop when a boy with alopecia walked by and could not take his eyes off me – I guess because he’d never seen anyone like him. That’s when I reached out to Alopecia UK as I realised that I have real-life experience than can support and help others going through what I went through as a child and teenager. It’s important to me that others benefit from my experience.”

Disclosures: None to declare.

Leila Asfour, MBChB, BSc, MRCP

Leila Asfour is a dermatologist. She has been involved in the development and recruitment for the Global Registry of Alopecia Areata Disease Severity and Treatment Safety (GRASS) in Australia.

Disclosures: Subinvestigator for research conducted by Pfizer and the Global Registry of Alopecia Areata Disease Severity and Treatment Safety (GRASS) outside of the submitted work.

Brett King, MD, PhD

Brett King is Associate Professor of Dermatology at Yale School of Medicine, New Haven, Connecticut, USA. King specializes in skin diseases recalcitrant to first-line therapies and the use of Janus kinase (JAK) inhibitors in the treatment of skin conditions, including alopecia areata.

Disclosures: AbbVie, Almirall, AltruBio, Amgen, AnaptysBio, Apogee Therapeutics, Aquestive, Arena Pharmaceuticals, ASLAN Pharmaceuticals, Bristol Myers Squibb, Concert Pharmaceuticals, Equillium, GSK, Horizon Therapeutics, Incyte, Janssen, LEO Pharma, Eli Lilly and Company, Merck, Otsuka Pharmaceuticals, Pfizer, Q32 Bio, Regeneron, Sanofi Genzyme, Soterios, Sun Pharma, Takeda, TWi Biotechnology.

Rodney Sinclair, MBBS, MD, FACD

Rodney Sinclair is a Professorial Associate in the Department of Medicine at the University of Melbourne, Victoria, Australia. He is also the co-founder of the Australasian Society for Dermatology Research (ASDR) and the Australasian Hair and Wool Research Society (AHWRS).

Disclosures: Pharmaceutical advisory board for Eli Lilly and Company, LEO Pharma, and Pfizer. Speaker bureaus for AbbVie, GSK, Novartis, and Pfizer. Principal investigator in clinical trials for AbbVie, Aerotech, Akesobio, Amgen, Arcutis Biotherapeutics, Arena Pharmaceuticals, Ascend Laboratories, AstraZeneca, Bayer AG, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Coherus BioSciences, Connect Biopharma, Dermira, Eli Lilly and Company, Galderma, GSK, Janssen, MedImmune, Merck & Co, Merck Sharp & Dohme, Novartis, Oncobiologics, Pfizer, Principia, Regeneron, Reistone Biopharma, Roche, Samson Clinical, Sanofi–Genzyme, Sun Pharma, UCB, Valeant, and Zai Lab.

Lynn Wilks 

Patient advocate and Alopecia UK trustee Lynn Wilks is a retired NHS Biomedical Scientist and current policy specialist. Wilks was first diagnosed with alopecia 20 years ago and uses her experiences with alopecia to advise healthcare professionals and support better access to effective treatments.

Disclosures: None to declare.